Pfizer has developed a new mobile health app named Moodivator to help motivate to help motivate and encourage the millions of adults who experience depression. An estimated 1 in 15 adults experience at least one major depressive episode in any given year. To help support, encourage and motivate people with depression, the new app is designed to help patients set and achieve manageable goals—in areas from wellness to treatment—and turn those goals into routines. Patients can regularly log your
Read More
Pfizer
IBM, Pfizer Partner for IoT Collaboration to Transform Parkinson’s Disease Care
Pfizer and IBM are teaming up on a first-of-its-kind research Internet of Things (IoT) collaboration to develop remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental IoT approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The research collaboration goal is to obtain a better
Read More
Pfizer, Galvanize Partner to Launch Health & Wellness Innovation Program
Galvanize and Pfizer Consumer Healthcare (PCH) has announced a joint health and wellness innovation program that will enable up to ten startup companies specializing in the development of potential solutions for improved sleep, stress management, energy, aging and nutrition to access Galvanize’s network of technical talent and investors.
The first cohort of companies will be jointly selected by Galvanize and Pfizer Consumer Healthcare for a six-month program beginning on March 7, 2016, that
Read More
Pfizer Pumps $46M in Early-Stage Scientific Innovations
Pfizer is expanding its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer’s core interests.
The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics
Read More
